Im Erasmushaus,
Bäumleingasse 18,
4051 Basel,
Switzerland
Prinzregentenstr. 64,
81675 München,
Germany
Innosuisse has awarded Nuclidium with a €1 million grant to further advance its development of a proprietary platform of novel PET tracers based on Copper-61.
NUCLIDIUM was featured by BioCentury in an Emerging Company Profile highlighting the company’s unique copper-based approach in targeted radiotheranostic development
NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress